{
    "code": "02025129",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025129",
    "time": "2019-11-08 03:03:47",
    "許可證字號": "衛署藥輸字第025129號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "113\/12\/16",
    "發證日期": "98\/12\/16",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202512906",
    "中文品名": "拜瑞妥膜衣錠10毫克",
    "英文品名": "Xarelto film-coated tablets 10mg",
    "適應症": "1. 用於非瓣膜性心房顫動(non-valvular atrial fibrillation)且有下列至少一項危險因子者成人病患，預防中風及全身性栓塞(systemic embolism)。危險因子例如：心衰竭、高血壓、年齡大於等於75歲、糖尿病、曾發生腦中風或短暫性腦缺血發作(transient ischemic attack)。\r\n2. Rivaroxaban用於靜脈血栓高危險群(曾發生有症狀之靜脈血栓症)病患，以預防其於接受下肢重大骨科手術後之靜脈血栓栓塞症(VTE)。\r\n3. 治療深部靜脈血栓與肺栓塞及預防再發性深部靜脈血栓與肺栓塞。\r\n說明：各適應症之用法用量，請參閱「用法用量」欄。",
    "劑型": "116膜衣錠",
    "包裝": "2~1000錠鋁箔盒裝",
    "": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "-->\r\n                    \r\n                        \r\n                            標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": "RIVAROXABAN",
    "主製造廠": {
        "申請商名稱": "1426201100  臺灣拜耳股份有限公司",
        "申請商地址": "台北市信義區信義路五段7號台北101大樓之53至54樓",
        "主製造廠": "",
        "製造廠名稱": "FDE0438200  Bayer AG"
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200099500",
            "成分名稱": "RIVAROXABAN",
            "含量描述": "",
            "含量": "10.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Xarelto_CCDS14 TW13, CCDS11 TW09_042019_排版_FINAL-108-09-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025129&Seq=013&Type=9"
        },
        {
            "title": "Xarelto10mg鋁箔-107-06-11(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025129&Seq=005&Type=8"
        },
        {
            "title": "Xarelto10mg外盒-107-06-11(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025129&Seq=004&Type=8"
        }
    ]
}